Skip to main content

Beatriz Minguez Rosique

Institutions of which they are part

Main researcher
Liver Diseases
Vall Hebron Institut de Recerca

Beatriz Minguez Rosique

Institutions of which they are part

Main researcher
Liver Diseases
Vall Hebron Institut de Recerca

Projects

Malalties Hepatobiliars (GRC)

IP: -
Collaborators: Beatriz Minguez Rosique, Immaculada Raurell Saborit, Lluís Viladomiu Catà, Antonio González Fernández, Lluis Castells Fusté, Maria del Mar Riveiro Barciela, Silvia Sauleda Oliveras, Maria Buti Ferret, Josep Quer Sivila, Josep Gregori Font, Maria Nieves Martell Pérez-Alcalde, Damir Garcia Cehic, Juan Ignacio Esteban Mur, Meritxell Ventura Cots, Macarena Simon-Talero Horga, Joan Genescà Ferrer, David Tabernero Caellas
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 65000
Reference: 2014 SGR 421
Duration: 01/01/2014 - 31/12/2016

Lipotoxicity, Hepatic Steatosis and Hepatocarcinoma: role of the Armc10/Armcx family of mitochondrial proteins

IP: Beatriz Minguez Rosique
Collaborators: Monica Higuera Urbano
Funding agency: Fundació La Marató de TV3
Funding: 98437.5
Reference: 20133732
Duration: 14/03/2014 - 13/03/2017

Terapia molecular del carcinoma hepatocelular mediante inhibición de las vías de señalización PI3K/AKT y EFGR

IP: -
Collaborators: Beatriz Minguez Rosique
Funding agency: Ministerio de Educación, Cultura y Deporte
Funding:
Reference: FULBRIGHT_01_2008
Duration: 01/12/2008 - 30/11/2009

Efectos de la infusión de albúmina en el episodio de encefalopatía hepática. Estudio aleatorio y multicéntrico en pacientes con cirrosis hepática

IP: -
Collaborators: Beatriz Minguez Rosique, Meritxell Ventura Cots
Funding agency: Instituto de Salud Carlos III
Funding: 71390
Reference: PI070641
Duration: 01/01/2008 - 30/12/2011

Related news

The consensus establishes recommendations that could correct the current disparities related to muscle mass, weight and height and would allow for more precise prioritization of patients who require transplants more urgently.

Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

Related professionals

Imanol Otaegui Irurueta

Imanol Otaegui Irurueta

Cardiovascular Diseases
Read more
José Raul Herance Camacho

José Raul Herance Camacho

Head of group
Molecular Medical Imaging
Read more
Thaïs Murciano Carrillo

Thaïs Murciano Carrillo

Childhood Cancer and Blood Disorders
Read more
M. Mercè Fabregat  Bosch

M. Mercè Fabregat Bosch

Reconstructive Surgery of the Locomotor System
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.